What is the share price of Thyrocare Technologies Ltd (THYROCARE) today?
The share price of THYROCARE as on 10th March 2026 is ₹374.30. The stock prices are volatile and keep changing through the day depending upon various factors and market conditions.What is the return on Thyrocare Technologies Ltd (THYROCARE) share?
The past returns of Thyrocare Technologies Ltd (THYROCARE) share are- Past 1 week: -0.89%
- Past 1 month: -9.41%
- Past 3 months: -11.66%
- Past 6 months: -13.18%
- Past 1 year: 62.15%
- Past 3 years: 136.23%
- Past 5 years: 25.35%
What are the peers or stocks similar to Thyrocare Technologies Ltd (THYROCARE)?
The peers or stocks similar to Thyrocare Technologies Ltd (THYROCARE) include:What is the dividend yield % of Thyrocare Technologies Ltd (THYROCARE) share?
The current dividend yield of Thyrocare Technologies Ltd (THYROCARE) is 1.87.What is the market cap of Thyrocare Technologies Ltd (THYROCARE) share?
Market capitalization, short for market cap, is the market value of a publicly traded company's outstanding shares. The market cap of Thyrocare Technologies Ltd (THYROCARE) is ₹5957.56 Cr as of 10th March 2026.What is the 52 week high and low of Thyrocare Technologies Ltd (THYROCARE) share?
The 52-week high of Thyrocare Technologies Ltd (THYROCARE) is ₹536.66 and the 52-week low is ₹219.56.What is the PE and PB ratio of Thyrocare Technologies Ltd (THYROCARE) stock?
The P/E (price-to-earnings) ratio of Thyrocare Technologies Ltd (THYROCARE) is 65.10. The P/B (price-to-book) ratio is 10.89.Which sector does Thyrocare Technologies Ltd (THYROCARE) belong to?
Thyrocare Technologies Ltd (THYROCARE) belongs to the Health Care sector & Hospitals & Diagnostic Centres sub-sector.How to buy Thyrocare Technologies Ltd (THYROCARE) shares?
You can directly buy Thyrocare Technologies Ltd (THYROCARE) shares on Tickertape. Simply sign up, connect your demat account and place your order.
Thyrocare Technologies Ltd
THYROCARE Share Price
NSE₹374.300.23% (-0.85)
High
—
—
Low
—
—
Returns
—
—
1D
1W
1M
1Y
5Y
Max
SIP
1D
1W
1M
1Y
5Y
Max
SIP
THYROCARE Stock Scorecard
Performance
AvgPrice return has been average, nothing exciting
Valuation
HighSeems to be overvalued vs the market average
Growth
LowLagging behind the market in financials growth
Profitability
HighShowing good signs of profitability & efficiency
Entry point
GoodThe stock is underpriced and is not in the overbought zone
Red flags
AvgThe stock has a moderate number of red flags
How to use scorecard? Learn more
THYROCARE Performance & Key Metrics
THYROCARE Performance & Key Metrics
| No LabelNo Label | PB RatioPB Ratio | Dividend YieldDiv. Yield |
|---|---|---|
| 43.29 | 10.89 | 1.87% |
| Sector PESector PE | Sector PBSector PB | Sector Div YldSctr Div Yld |
|---|---|---|
| 36.93 | 5.82 | 0.58% |
100%
Analysts have suggested that investors can buy this stock
from 3 analysts
Price Upside
Earnings Growth
Rev. Growth
THYROCARE Company Profile
Thyrocare Technologies Limited is a diagnostic chain company which offers a range of medical diagnostic tests and profiles of tests that center on early detection and management of disorders and diseases.
APOLLOHOSP
PE Ratio
77.60
77.60
1Y Return
26.89%
26.89%
Buy Reco %
86.21
86.21
MAXHEALTH
PE Ratio
94.34
94.34
1Y Return
8.17%
8.17%
Buy Reco %
81.82
81.82
FORTIS
PE Ratio
85.99
85.99
1Y Return
41.93%
41.93%
Buy Reco %
82.35
82.35
PE Ratio
44.99
44.99
1Y Return
10.57%
10.57%
Buy Reco %
80.00
80.00
ASTERDM
PE Ratio
6.40
6.40
1Y Return
57.42%
57.42%
Buy Reco %
100.00
100.00
THYROCARE Sentiment Analysis
THYROCARE Sentiment Analysis
New
Crisp summary & key insights to decode earnings calls instantly
THYROCARE Stock Summary · February 2026
In Q3 FY '26, Thyrocare demonstrated robust financial performance, reporting an 18% year-on-year revenue growth driven by its franchise and partnership businesses, while gross margins improved significantly due to effective cost management strategies. The company is strategically expanding into Africa and enhancing its operational capabilities through new leadership and partnerships, positioning itself as a leader in the diagnostics sector. Despite facing challenges from a competitive landscape and tighter credit controls, management remains cautiously optimistic about sustaining a long-term organic growth rate of 12-15%. Additionally, ongoing investments in specialty services and technology integration are expected to bolster its market presence and operational efficiency, while the anticipated rise in GLP-1 medication usage may further drive diagnostic testing demand.
THYROCARE Stock Growth Drivers
THYROCARE Stock Growth Drivers
8Franchise Business Growth
Thyrocare's franchise business has shown significant growth, with the active franchisee base reaching a record
Recognition and Awards
Thyrocare has received notable recognition at the National Diagnostics Forum & Awards, winning two prestigious
THYROCARE Stock Challenges
THYROCARE Stock Challenges
6Revenue Decline and Normalization Challenges
The company has experienced a decline in revenue from its franchise business, primarily due to
Growth Rate Concerns
The reported growth figures indicate a consolidated growth of 18%, but this includes a significant
THYROCARE Forecast
THYROCARE Forecasts
Price
Revenue
Earnings
THYROCARE Share Price Forecast
THYROCARE Share Price Forecast
2026
Current
₹374.30
Baseline
Forecast for Mar 2027
High
₹—
Median
₹—
Low
₹—
All values in ₹
2026
Current
₹374.30
Baseline
Forecast for Mar 2027
High
₹—
Median
₹—
Low
₹—
All values in ₹
THYROCARE Company Revenue Forecast
THYROCARE Company Revenue Forecast
2025
Current
₹702.18
Baseline
Forecast for Mar 2026
High
₹—
Median
₹—
Low
₹—
All values in ₹ cr.
2025
Current
₹702.18
Baseline
Forecast for Mar 2026
High
₹—
Median
₹—
Low
₹—
All values in ₹ cr.
THYROCARE Stock EPS (Earnings Per Share) Forecast
THYROCARE Stock EPS (Earnings Per Share) Forecast
2025
Current
₹5.76
Baseline
Forecast for Mar 2026
High
₹—
Median
₹—
Low
₹—
All values in ₹
2025
Current
₹5.76
Baseline
Forecast for Mar 2026
High
₹—
Median
₹—
Low
₹—
All values in ₹
THYROCARE
THYROCARE
Income
Balance Sheet
Cash Flow
Quarterly Normal View
THYROCARE Income Statement
THYROCARE Income Statement
Quarterly Normal View
| Quarter | sep 2023 | dec 2023 | mar 2024 | jun 2024 | sep 2024 | dec 2024 | mar 2025 | jun 2025 | sep 2025 | dec 2025 | ||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Total Revenue | 150.53 | 137.60 | 157.74 | 160.52 | 179.97 | 169.93 | 191.75 | 197.93 | 219.86 | 200.79 | ||||||||||
Operating & Other expenses | 110.48 | 103.15 | 120.66 | 114.62 | 129.36 | 124.35 | 130.09 | 135.26 | 145.18 | 143.86 | ||||||||||
EBITDA | 40.05 | 34.45 | 37.08 | 45.90 | 50.61 | 45.58 | 61.66 | 62.67 | 74.68 | 56.93 | ||||||||||
| Depreciation/Amortization | 10.65 | 13.47 | 13.06 | 11.36 | 13.07 | 17.06 | 13.77 | 11.41 | 11.51 | 21.63 | ||||||||||
| PBIT | 29.40 | 20.98 | 24.02 | 34.54 | 37.54 | 28.52 | 47.89 | 51.26 | 63.17 | 35.30 | ||||||||||
| Interest & Other Items | 1.13 | 1.07 | 1.12 | 0.99 | 0.76 | 0.60 | 0.70 | 0.78 | 0.59 | -0.09 | ||||||||||
| PBT | 28.27 | 19.91 | 22.90 | 33.55 | 36.78 | 27.92 | 47.19 | 50.48 | 62.58 | 35.39 | ||||||||||
| Taxes & Other Items | 7.93 | 4.56 | 5.12 | 9.38 | 10.11 | 8.81 | 25.49 | 11.55 | 14.59 | 6.38 | ||||||||||
| Net Income | 20.34 | 15.35 | 17.78 | 24.17 | 26.67 | 19.11 | 21.70 | 38.93 | 47.99 | 29.01 | ||||||||||
| EPS | 1.28 | 0.93 | 1.18 | 1.51 | 1.66 | 1.19 | 1.39 | 2.45 | 3.02 | 1.82 |
THYROCARE Company Updates
FY 2026FY 2026
Investor Presentation
Jan 28PDF
Oct 14PDF
Jul 23PDF
Jul 23PDF
THYROCARE Stock Peers
THYROCARE Past Performance & Peer Comparison
THYROCARE Past Performance & Peer Comparison
Comparing 3 stocks from
Health CareHospitals & Diagnostic Centres
Compare valuation on Screener
Health CareHospitals & Diagnostic Centres
Valuation
Technical
Forecast
Compare valuation on Screener| Stock | PE RatioPE Ratio | PB RatioPB Ratio | Div. YieldDividend Yield |
|---|---|---|---|
| Thyrocare Technologies Ltd | 65.10 | 10.89 | 1.87% |
| Apollo Hospitals Enterprise Ltd | 77.60 | 10.11 | 0.16% |
| Max Healthcare Institute Ltd | 94.34 | 10.82 | 0.14% |
| Fortis Healthcare Ltd | 85.99 | 7.26 | 0.11% |
THYROCARE Stock Price Comparison
Compare THYROCARE with any stock or ETFCompare THYROCARE with any stock or ETF
THYROCARE
THYROCARE Holdings
THYROCARE Shareholdings
THYROCARE Promoter Holdings Trend
THYROCARE Promoter Holdings Trend
Decreased Total Promoter Holding
Increasing promoter holding is considered good and reflects management’s positive view about the future outlook
In last 6 months, promoter holding in the company has decreased by 10.13%
High Pledged Promoter Holding
Lower pledged promoter holdings is considered better
A significant proportion of promoter holdings is pledged
THYROCARE Institutional Holdings Trend
THYROCARE Institutional Holdings Trend
Increased Total Retail Holding
Increasing retail holding can be considered bad as it can reflect that institutions and promoters are selling their stake which is being absorbed by retail investors.
In last 3 months, retail holding in the company has increased by 1.50%
Foreign Institutional Holding
Foreign Institutional Holding is quantum of stock held by foreign large-quantities-trading entities. Increasing value indicates growing support and comfort for the stock
In last 3 months, foreign institutional holding of the company has almost stayed constant
THYROCARE Shareholding Pattern
THYROCARE Shareholding Pattern
THYROCARE Shareholding History
THYROCARE Shareholding History
Foreign Institutions
Mutual Funds Invested in THYROCARE
Mutual Funds Invested in THYROCARE
No mutual funds holding trends are available
Top 5 Mutual Funds holding Thyrocare Technologies Ltd
| Funds (Top 5) | The rupee value of the stock held by the fund divided by the stock’s market cap Market-cap held | Percentage of the fund’s portfolio invested in the stock Weight | Change in the portfolio weight of the stock over the last 3 months 3M holding change | The rank of the stock in the fund’s portfolio based on its weight in the portfolio along with the change in the rank over the last 3 months Portfolio rank(3M change) |
|---|---|---|---|---|
The rupee value of the stock held by the fund divided by the stock’s market cap 3.4069% | Percentage of the fund’s portfolio invested in the stock 0.30% | Change in the portfolio weight of the stock over the last 3 months -0.07% | The rank of the stock in the fund’s portfolio based on its weight in the portfolio along with the change in the rank over the last 3 months 109/260 (+1) | |
The rupee value of the stock held by the fund divided by the stock’s market cap 2.8955% | Percentage of the fund’s portfolio invested in the stock 2.08% | Change in the portfolio weight of the stock over the last 3 months -0.49% | The rank of the stock in the fund’s portfolio based on its weight in the portfolio along with the change in the rank over the last 3 months 18/39 (-5) | |
The rupee value of the stock held by the fund divided by the stock’s market cap 2.8830% | Percentage of the fund’s portfolio invested in the stock 1.38% | Change in the portfolio weight of the stock over the last 3 months -0.34% | The rank of the stock in the fund’s portfolio based on its weight in the portfolio along with the change in the rank over the last 3 months 58/88 (-2) |
Compare 3-month MF holding change on Screener
smallcases containing THYROCARE stock
smallcases containing THYROCARE stock
Looks like this stock is not in any smallcase yet.
THYROCARE Events
THYROCARE Events
THYROCARE Dividend Trend
Dividend Yield
Dividend return is one of the most important things to be considered while investing for long term. It is the additional return on top of what investors earn through price appreciation
Current dividend yield is 1.86%. An investment of ₹1,000 in the stock is expected to generate dividend of ₹18.64 every year
Dividends
Corp. Actions
Announcements
Legal Orders
Dividends
THYROCARE Dividend Trend
Dividend Yield
Dividend return is one of the most important things to be considered while investing for long term. It is the additional return on top of what investors earn through price appreciation
Current dividend yield is 1.86%. An investment of ₹1,000 in the stock is expected to generate dividend of ₹18.64 every year
THYROCARE Upcoming Dividends
THYROCARE Upcoming Dividends
No upcoming dividends are available
THYROCARE Past Dividends
THYROCARE Past Dividends
Cash Dividend
Ex DateEx DateOct 24, 2025
Interim
Interim | Div/Share: ₹7.00
Dividend/Share
₹7.00
Ex DateEx Date
Oct 24, 2025
Cash Dividend
Ex DateEx DateJul 25, 2025
Final
Final | Div/Share: ₹21.00
Dividend/Share
₹21.00
Ex DateEx Date
Jul 25, 2025
Cash Dividend
Ex DateEx DateAug 16, 2024
Final
Final | Div/Share: ₹18.00
Dividend/Share
₹18.00
Ex DateEx Date
Aug 16, 2024
Cash Dividend
Ex DateEx DateApr 20, 2023
Interim
Interim | Div/Share: ₹18.00
Dividend/Share
₹18.00
Ex DateEx Date
Apr 20, 2023
Cash Dividend
Ex DateEx DateMay 11, 2022
Interim
Interim | Div/Share: ₹15.00
Dividend/Share
₹15.00
Ex DateEx Date
May 11, 2022
THYROCARE Stock News & Opinions
THYROCARE Stock News & Opinions
Articles & Videos
Corporate
Thyrocare Technologies allots 3,624 equity shares under ESOS
Thyrocare Technologies has allotted 3,624 equity shares under ESOS on 02 March 2026. With this allotment, the paid up equity share capital has increased 15,91,65,315 equity shares of Rs 10 each. Powered by Capital Market - Live
1 week agoCapital Market - Live
Corporate
Thyrocare Technologies to declare Quarterly Results
Thyrocare Technologies will hold a meeting of the Board of Directors of the Company on 28 January 2026.Powered by Capital Market - Live
1 month agoCapital Market - Live
Spotlight
Thyrocare Technologies appoints Dr Ramesh Kinha as COO
Dr. Ramesh Kinha is a healthcare and diagnostics professional with over 17 years of experience. Before joining the company, he was Group Director ' Laboratory Services at Vijaya Diagnostic Centre and has held leadership roles at Apollo Health & Lifestyle, Medall Healthcare, Metropolis Healthcare, and SRL. He holds an MBBS and an MD (Pathology), has completed senior management programs from IIM Nagpur and ISB, and is an NABL Assessor. Thyrocare Technologies is India's first and foremost advanced fully automated laboratory chain with a strong presence PAN India. The company focuses on providing quality and affordable diagnostic services to laboratories and hospitals. Thyrocare has a quarterly active franchise count of more than 10,000 and has processed over 53.3 million diagnostic and screening investigations in Q2 FY26. The company reported an 82% jump in consolidated net profit to Rs 47.90 crore on a 22% rise in revenue from operations to Rs 216.53 crore in Q2 FY26 over Q2 FY25. Shares of Thyrocare Technologies shed 0.23% to Rs 441.30 on the BSE.Powered by Capital Market - Live
2 months agoCapital Market - Live
Corporate
Thyrocare Technologies allots 10.61 cr equity shares under bonus issue
Thyrocare Technologies has allotted 10,61,07,794 equity shares of Rs 10 each under bonus issue in ratio of 2:1. Post allotment, the paid up equity share capital has increased to 15,91,61,691 equity shares of Rs 10 each. Powered by Capital Market - Live
3 months agoCapital Market - Live
Corporate
Thyrocare Technologies announces resignation of Chief Commercial Officer
Thyrocare Technologies announced that Nitin Chugh, Chief Commercial Officer and part of the Senior Management Personnel of the company has resigned with effect from 30 November 2025. Powered by Capital Market - Live
3 months agoCapital Market - Live
Corporate
Thyrocare Technologies promoter offloads shares
Docon Technologies Private Limited ('Docon'), Promoter of Thyrocare Technologies has sold 53,32,860 equity shares of the Company through market trades on 24th October 2025 for an aggregate gross consideration of Rs. 667.69 crore (rounded off), at an average price of approximately Rs. 1,252.03 per share (rounded off). The number of shares sold constitutes approximately 10% of the total paid-up capital of the Company. Following this transaction, Docon continues to be a promoter of the Company. Post this transaction, the promoter shareholding in the Company stands reduced to 60.93% from the pre-transaction shareholding of 70.98%.Powered by Capital Market - Live
4 months agoCapital Market - Live
Corporate
Thyrocare Technologies fixes record date for interim dividend
Thyrocare Technologies has fixed 24 October 2025 as record date for interim dividend. Powered by Capital Market - Live
4 months agoCapital Market - Live
Corporate
Thyrocare Technologies declares bonus issue of 2:1
The Board of Thyrocare Technologies has approved issuance of bonus shares in the proportion of 2:1, i.e. 2 bonus equity shares of Rs 10 each for every 1 fully paid-up equity share held as on the record date. Also, the board has declared an interim dividend of INR 7 per equity share of the face value of Rs 10 each, pre-bonus issuancePowered by Capital Market - Live
4 months agoCapital Market - Live
Earnings
Thyrocare Technologies consolidated net profit rises 79.94% in the September 2025 quarter
Net profit of Thyrocare Technologies rose 79.94% to Rs 47.99 crore in the quarter ended September 2025 as against Rs 26.67 crore during the previous quarter ended September 2024. Sales rose 22.09% to Rs 216.53 crore in the quarter ended September 2025 as against Rs 177.36 crore during the previous quarter ended September 2024. ParticularsQuarter EndedSep. 2025Sep. 2024% Var. Sales216.53177.36 22 OPM %32.9527.06 - PBDT74.0949.85 49 PBT62.5836.78 70 NP47.9926.67 80 Powered by Capital Market - Live
4 months agoCapital Market - Live
Corporate
Board of Thyrocare Technologies recommends interim dividend
Thyrocare Technologies announced that the Board of Directors of the Company at its meeting held on 14 October 2025, inter alia, have recommended the interim dividend of Rs 7 per equity Share (i.e. 70%) , subject to the approval of the shareholders.Powered by Capital Market - Live
4 months agoCapital Market - Live
Over the last 5 years, revenue has grown at a yearly rate of 9.73%, vs industry avg of 13.46%
Over the last 5 years, market share decreased from 1.06% to 0.85%
Over the last 5 years, net income has grown at a yearly rate of 0.69%, vs industry avg of 42.5%